Physician profile
Carl E Bricca
NPI 1114925385
$4,150.10
in general payments reported to CMS, 2019-2025
33 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $614 · 2022: $119 · 2023: $726 · 2024: $829 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $878.61 | 2019-2024 | Dovato, Rukobia |
| Novo Nordisk INC | $550.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $293.33 | 2019-2025 | |
| Lilly USA, LLC | $250.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $233.08 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $229.43 | 2023-2025 | Linzess, Viberzi, Vraylar |
| Gilead Sciences, INC. | $208.07 | 2019-2023 | |
| Glaxosmithkline, LLC. | $206.90 | 2019-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.01 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $176.61 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $112.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $88.56 | 2024-2025 | |
| Allergan, INC. | $86.73 | 2019-2020 | |
| Janssen Biotech, INC. | $71.27 | 2019-2023 | Symtuza |
| E.R. Squibb & Sons, L.L.C. | $63.49 | 2019-2023 | Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $56.78 | 2019-2020 | |
| Amgen INC. | $46.84 | 2023 | Evenity, Prolia |
| Exact Sciences Corporation | $39.09 | 2024-2025 | Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $37.59 | 2025 | Pyrukynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.12 | 2019-2025 | Xifaxan |
| Eisai INC. | $32.54 | 2020 | |
| Sumitomo Pharma America, INC. | $29.27 | 2025 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $24.00 | 2019 | |
| Bausch Health US, LLC | $23.20 | 2023 | Aplenzin |
| Xeris Pharmaceuticals, INC. | $23.10 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $22.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.43 | 2020 | |
| Dexcom, INC. | $22.36 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $20.18 | 2019 | |
| Abbott Laboratories | $16.00 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.95 | 2025 | Rexulti |
| Radius Health, INC. | $15.92 | 2019 | |
| Theratechnologies INC. | $14.58 | 2024 | Trogarzo, Egrifta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Bricca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.